Grey Fox Wealth Advisors LLC Decreases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Grey Fox Wealth Advisors LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,163 shares of the biopharmaceutical company’s stock after selling 167 shares during the period. Grey Fox Wealth Advisors LLC’s holdings in Gilead Sciences were worth $256,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. PCA Investment Advisory Services Inc. bought a new stake in Gilead Sciences during the second quarter worth about $25,000. Tompkins Financial Corp raised its holdings in Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the last quarter. OFI Invest Asset Management purchased a new position in shares of Gilead Sciences during the third quarter valued at approximately $26,000. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Finally, Union Savings Bank bought a new stake in Gilead Sciences during the second quarter valued at approximately $29,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD traded up $0.51 on Thursday, hitting $73.52. 1,969,193 shares of the company’s stock were exchanged, compared to its average volume of 7,505,220. Gilead Sciences, Inc. has a fifty-two week low of $71.37 and a fifty-two week high of $87.86. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The firm has a 50-day moving average price of $75.38 and a 200-day moving average price of $77.32. The stock has a market cap of $91.54 billion, a price-to-earnings ratio of 16.38, a P/E/G ratio of 0.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same period last year, the firm earned $1.67 EPS. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.19%. Gilead Sciences’s payout ratio is presently 68.44%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GILD. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and cut their target price for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Cantor Fitzgerald lowered their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Royal Bank of Canada lowered their target price on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. Finally, Mizuho lowered their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $85.36.

Insider Activity

In other news, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the transaction, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the sale, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the completion of the sale, the insider now owns 82,729 shares in the company, valued at $7,050,992.67. The disclosure for this sale can be found here. In the last quarter, insiders have sold 15,242 shares of company stock valued at $1,277,726. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.